ADAMTS13, FVIII, von Willebrand factor, ABO blood group assessment in preeclampsia

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2162-2166

  Alpoim, Patrícia N ^a   Gomes, Karina B ^a   Godoi, Lara C ^a   Rios, Danyelle R ^a   Carvalho, Maria G ^a   Fernandes, Ana P ^a   Dusse, Luci M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

ABO blood groups; ADAMTS13; Factor viii; Preeclampsia; VonWillebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 7; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ANTIGEN DETECTION; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP O; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATION PERIOD; HUMAN; MAJOR CLINICAL STUDY; PHENOTYPE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; VON WILLEBRAND FACTOR;

EID: 80053639803     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.07.030     Document Type: Article

References (49)

1. Gifford R.W., August P.A., Cunningham G., et al. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol 2000, 183:S1-S22.
2. Sibai B.M., Caritis S.N., Thom E., et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant-women. N Engl J Med 1993, 329:1213-1218.
3. Molvarec A., Jermendy A., Nagy B., et al. Association between tumor necrosis factor (TNF)-alpha G-308A gene polymorphism and preeclampsia complicated by severe fetal growth restriction. Clin Chim Acta 2008, 392:52-57.
4. Moake J.L., Rudy C.K., Troll J.H., et al. Unusually large plasma factor-- Von Willebrand-factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 1982, 307:1432-1435.
5. Anstadt M.P., Carwile J.M., Guill C.K., et al. Relapse of thrombotic thrombocytopenic purpura associated with decreased VWF cleaving activity. Am J Med Sci 2002, 323:281-284.
6. Ouvina S.M., La Greca R.D., Zanaro N.L., et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type II patients. Thromb Res 2001, 102:107-114.
7. Sumpio B.E., Riley J.T., Dardik A. Cells in focus: endothelial cell. Int J Biochem Cell Biol 2002, 34:1508-1512.
8. Ruggeri Z.M. Von Willebrand factor, platelets and endothelial cell interactions. Thromb Haemost 2003, 1:1335-1342.
9. Ruggeri Z.M. Von Willebrand factor. J Clin Invest 1997, 99:559-564.
10. Jager A., van Hinsbergh V.W.M., Kostense P.J., et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects - the Hoorn study. Arterioscler Thromb Vasc Biol 1999, 19:3071-3078.
11. Furlan M., Robles R., Galbusera M., et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998, 339:1578-1584.
12. Tsai H.M., Lian E.C.Y. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
13. Zheng X.L., Chung D., Takayama T.K., et al. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 2001, 276:41059-41063.
14. Fujikawa K., Suzuki H., McMullen B., et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
15. Manea M., Kristoffersson A., Tsai H.M., et al. ADAMTS13 phenotype in plasma from normal individuals and patients with thrombotic thrombocytopenic purpura. Eur J Pediatr 2007, 166:249-257.
16. Ruggeri Z.M., Mannucci P.M., Lombardi R., et al. Multimeric composition of factor-VIII Von Willebrand-factor following administration of ddavp - implications for patho-physiology and therapy of von Willebrands disease subtypes. Blood 1982, 59:1272-1278.
17. Sadler J.E., Miyata T., George J.N. Recent advances in thrombotic thrombocytopenic purpura. Hematol Amerc Soc Hemat Edu Progr 2004, 407-423.
18. Rieger M., Mannucci P.M., Hovinga J.A.K., et al. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood 2005, 106:1262-1267.
19. Kamphuisen P.W., Eikenboom J.C.J., Bertina R.M. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001, 21:731-738.
20. Morelli V.M., De Visser M.C.H., Vos H.L., et al. ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden. Thromb Haemost 2005, 3:183-185.
21. Orstavik K.H., Magnus P., Reisner H., et al. Factor-VIII and factor-IX in a twin population - evidence for a major effect of abo locus on factor-VIII level. Am J Hum Genet 1985, 37:89-101.
22. Shima M., Fujimura Y., Nishiyama T., et al. ABO blood-group genotype and plasma von-Willebrand-factor in normal individuals. Vox Sang 1995, 68:236-240.
23. Sousa N.C., Anicchino-Bizzacchi J.M., Locatelli M.F., et al. The relationship between ABO groups and subgroups, factor VIII and von Willebrand factor. Haematologica 2007, 92:236-239.
24. Jick H., Westerho B., Vessey M.P., et al. Venous thromboembolic disease and abo blood type - a cooperative study. Lancet 1969, 1:539.
25. Larsen T.B., Johnsen S.P., Gislum M., et al. ABO blood groups and risk of venous thromboembolism during pregnancy and the puerperium. A population-based, nested case-control study. Thromb Haemost 2005, 3:300-304.
26. Pike L.A., Dickins A.M. ABO blood groups and toxaemia of pregnancy. BMJ 1954, 2:321-323.
27. Dickins A.M., Richardson J.R.E., Pike L.A., et al. Further observations on ABO blood-group frequencies and toxaemia of pregnancy. BMJ 1955, 1:776-777.
28. Pearson M.G., Pinker G.D. ABO blood groups and toxaemia of pregnancy. BMJ 1955, 1:777-778.
29. May D. Maternal blood group-A and pre-eclampsia. BMJ 1973, 4:738.
30. Harlap S., Davies A.M. Maternal blood-group a and pre-eclampsia. BMJ 1974, 3:171-172.
31. Spinillo A., Capuzzo E., Baltaro F., et al. Case-control study of maternal blood-group and severe preeclampsia. J Hum Hypertens 1995, 9:623-625.
32. Hiltunen L.M., Laivuori H., Rautanen A., et al. Blood group AB and factor V Leiden as risk factors for pre-eclampsia: a population-based nested case-control study. Thromb Res 2009, 124:167-173.
33. Thornton C.A., Bonnar J. Factor-VIII-related antigen and factor-VIII coagulant activity in normal and pre-eclamptic pregnancy. BJOG 1977, 84:919-923.
34. Hulstein J.J.J., Heimel P.J.V., Franx A., et al. Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. Thromb Haemost 2006, 4:2569-2575.
35. Lattuada A., Rossi E., Calzarossa C., et al. Mild to moderate reduction of a von Willebrand factor cleaving protease (ADAMTS13) in pregnant women with HELLP microangiopathic syndrome. Haematologica 2003, Vol. 88:1029-1034.
36. de Boer K., ten Cate J.W., Sturk A., Borm J.J., Treffers P.E. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obst Gynecol 1989, 160:95-100.
37. España F., Gilabert J., Aznar J., et al. Complex of active protein C with α1-antitrypsin in normal pregnancy and in severe preeclampsia. Am J Obst Gynecol 1991, 164:1310.
38. Redman C.W.G., Sacks G.P., Sargent I.L. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obst Gynecol 1999, 180:499-506.
39. Dusse L.M., Rios D.R.A., Pinheiro M.B., et al. Pre-eclampsia: relationship between coagulation, fibrinolysis and inflammation. Clin Chim Acta 2011, 412:17-21.
40. Szarka A., Rigó J., Lázár L., Beko G., Molvarec A. Circulating cytokines, chemokines and adhesion molecules in normal pregnancy and preeclampsia determined by multiplex suspension array. BMC Immunol 2010, 11:59.
41. Manea M., Tati R., Karlsson J., Bekassy Z.D., Karpman D. Biologically active ADAMTS13 is expressed in renal tubular epithelial cells. Pediatr Nephrol 2010, 25:87-96.
42. Crawley J.T., Lam J.K., Rance J.B., et al. Proteolytic inactivation of ADAMTS13 by thrombin and plasmin. Blood 2005, 105:1085-1093.
43. Ono T., Mimuro J., Madoiwa S., et al. Severe secondary deficiency of von Willebrand factor-cleaving protease ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006, 107:528-534.
44. Stepanian A., Cohen-Moatti M., Sanglier T., et al. Von Willebrand Factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology. Arterioscler Thromb Vasc Biol 2011, 31:1703-1709.
45. Molvarec A., Rigo J., Boze T., et al. Increased plasma von Willebrand factor antigen levels but normal von Willebrand factor cleaving protease (ADAMTS13) activity in preeclampsia. Thromb Haemost 2009, 101:305-311.
46. Zhang D., Xiao J., Huang H., et al. Von Willebrand factor antigen and ADAMTS13 activity assay in pregnant women and severe preeclamptic patients. J Huazhong Univ Sci Technolog Med Sci 2010, 30:777-780.
47. Roberts J.M., Lain K.Y. Recent insights into the pathogenesis of pre-eclampsia. Placenta 2002, 23:359-372.
48. Savage B., Ruggeri Z.M. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein-IIb-IIIa on nonactivated platelets. J Biol Chem 1991, 266:11227-11233.
49. Mannucci P.M., Capoferri C., Canciani M.T. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004, 126:213-218.